Menu
Back to Journals » Drug Design, Development and Therapy » Volume 14
Minoxidil and Its Use in Hair Disorders: A Review [Corrigendum]
Authors Suchonwanit P , Thammarucha S, Leerunyakul K
Received 29 January 2020
Accepted for publication 29 January 2020
Published 10 February 2020 Volume 2020:14 Pages 575—576
Suchonwanit P, Thammarucha S, Leerunyakul K. Drug Des Devel Ther. 2019;13:2777–2786.
On page 2781, Androgenetic alopecia section, last paragraph, “A combination of low-dose minoxidil 2.5 mg and spironolactone 25 mg in patients with FPHL showed preferable outcomes with decrease hair shedding and improved hair density. The mean severity score reduced to 2.3 at 6 months and 2.6 at 12 months. Mild adverse effects including urticaria, postural hypotension, and facial hypertrichosis were reported.” should read “A combination of low-dose minoxidil 0.25 mg and spironolactone 25 mg in patients with FPHL showed preferable outcomes with decrease hair shedding and improved hair density. Mean reduction in hair shedding score was 2.3 at 6 months and 2.6 at 12 months. Mild adverse effects including urticaria, postural hypotension, and facial hypertrichosis were reported.”
Following feedback from a reader, we found 1) the incorrect dosage was listed for minoxidil and 2) the reduction in severity score relates to the visual-analogue Sinclair hair shedding scale.
The authors apologize for these errors.
Read the original article
© 2020 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.
By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.